Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Scynexis Inc
NASDAQ SCYX
Data sourced from
and
and
Scynexis Inc Working Capital to Current Liabilities Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -13.33%
Scynexis Inc Working Capital to Current Liabilities Ratio 5 year CAGR is -13.33% for the Trailing 12 Months (TTM) ending March 31, 2024, a -85.51% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Scynexis Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 4.23, a -33.92% change year over year.
-
Scynexis Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 6.40, a 97.08% change year over year.
-
Scynexis Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 3.25, a -10.71% change year over year.
-
Scynexis Inc Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 3.63, a -34.58% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: SCYX
| CEO | Dr. Marco Taglietti M.D. |
| IPO Date | May 2, 2014 |
| Location | United States |
| Headquarters | 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548 |
| Employees | 29 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Key trends
Similar companies
Eagle Pharmaceuticals Inc
NA
NA
Phibro Animal Health Corporation
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email